Navigation Links
Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
Date:6/17/2011

DALLAS and NEW YORK, June 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.  Together with its marketing partner Jian An, RHEI Pharmaceuticals completed the required process required to satisfy all requirements to receive marketing approval in China and its other South East Asian territories.  RHEI has advised Access of the next steps the SFDA will take to grant approval in its territories and anticipates receiving marketing approval in the second half of this year.

As part of its licensing agreement with Access, RHEI is responsible for obtaining the necessary regulatory approvals for MuGard.  Access and RHEI recently signed a $30 million supply agreement for MuGard to ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. In addition, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals ("Jian An") Limited in Shenzhen, China to leverage Jian An's extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan. Jian An is headquartered in Shenzhen, China and has a 25-year history of selling pharmaceutical and other medical products in the China market.  Jian An has 1400 sales representatives covering all majors centers in China through 169 sales offices.  

With Jian An's sales and marketing infrastructure, the supply agreement and the letter of acceptance, Access Pharmaceuticals' commercialization efforts remain on track in China.
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
(Date:7/30/2015)... Calif. , July 30, 2015  Cleave ... and Trademark Office has granted the company a ... covering Cleave,s lead molecule CB-5083. This ... as inhibitors of p97," U.S. 9,062,026, allows for ... a first-in-class, highly selective oral inhibitor of p97, ...
(Date:7/30/2015)... Flexpoint Ford, a private equity firm focused ... that it has entered into a partnership with ... form Kastle Therapeutics, LLC (Kastle).  The new company, headquartered ... acquiring, developing and commercializing pharmaceuticals targeted toward diseases with ... therapies already approved for marketing, as well as clinical ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... DIEGO, Feb. 6, 2012   Neurelis, Inc. today announced ... (FDA) has cleared an Investigational New Drug application ... of NRL-1 for the treatment of acute breakthrough ... late 2011, Neurelis filed the IND based upon ...
... Association (PCMA) launched a new ad campaign in Oregon ... (PBMs).  The ad campaign – "That,s What PBMs ... , PBMs lower costs for employers, unions, and consumers ... , PBMs help patients make informed prescription drug decisions ...
Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2PCMA Launches New Oregon Ad Campaign: 'That's What PBMs Do' 2
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels & Wheels ... Waycross, Georgia. Start time will be 7:30 AM. The duathlon is a 2 mile run, ... swim in Laura Walker Lake, a 13 mile bike, and a 3 mile run. ...
(Date:7/31/2015)... ... July 31, 2015 , ... With the recent buzz ... individuals who remain undiagnosed, treatment options for patients are becoming more prevalent than ... therapy due to its overall lack of comfort and highly invasive nature, oral ...
(Date:7/30/2015)... FL (PRWEB) , ... July 31, 2015 , ... On ... first meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. ... the event of an overdose is largely perpetuating the heroin crisis in North Florida. ...
(Date:7/30/2015)... , ... July 30, 2015 , ... OSF Healthcare ... results from the 2015 Most Wired Survey conducted by Hospitals & Health Networks. This ... system owned and operated by The Sisters of the Third Order of St. ...
(Date:7/30/2015)... ... 2015 , ... In a meaningful ritual intended to symbolize a final farewell ... have created an addiction graveyard. Sharing this with the public comes at a unique ... Hudson . Hudson (1945-2015) fell in love with the desert when he moved from ...
Breaking Medicine News(10 mins):Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... , , WASHINGTON, July 31 ... for Tobacco-Free Kids: , , (Logo: ... D.C. Council has taken an important step to protect the District,s kids ... cigarette tax by 50 cents to $2.50 per pack - the seventh ...
... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
... , , , Campaign ... After 4 months of college students and others wrestling with ... picked two winners for its nationwide sign design contest. The victors ... who is entering law school this fall at the University of ...
... , ALBANY, N.Y., July 31 ... New York throughout the week of August 3 - 7 ... New Yorkers access information on programs that provide prescription medicines for ... 8.2 percent, compared to 5.2 percent a year ago, the ...
... , , Partnership for ... WASHINGTON, July 31 The House Energy and Commerce ... legislation that would prohibit cost-sharing to Medicaid patients for recommended ... was supported by Partnership for Prevention, the American College of ...
... WASHINGTON, July 31 Last night, U.S. Rep. Lois Capps ... H.R. 3200, that would specifically include abortion in the health care ... Council Action President Tony Perkins had this to say on the ... up: , , "It has been clear ...
Cached Medicine News:Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 3Health News:House Committee Approves Amendment Eliminating Cost-Sharing for Medicaid Preventive Services 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2
... pacing wire design offers reliable ... in the atrium and ventricle ... in one lead design. The ... ventricle are color-coded for easy ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: